Mackenzie Financial
MDGL icon

Mackenzie Financial’s Madrigal Pharmaceuticals MDGL Stock Holding History

Mackenzie Financial’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-799
Closed -$213K – 1587
2024
Q1 		$213K Buy
+799
New +$188K ﹤0.01% 1317
2023
Q2 		– Sell
-974
Closed -$236K – 1586
2023
Q1 		$236K Buy
+974
New +$265K ﹤0.01% 1288

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Mackenzie Financial's MDGL Position: Q2 2024 in Review

Mackenzie Financial sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2024, closing a stake of 799 shares — an estimated $213K sold.

Mackenzie Financial first reported a position in MDGL in Q1 2023 and held it in 2 quarters. The position peaked at $236K in Q1 2023. 257 funds tracked by Wall St. Rank hold MDGL as of Q2 2024.

  • Mackenzie Financial reported no remaining Madrigal Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Mackenzie Financial sold 799 Madrigal Pharmaceuticals shares in Q2 2024, an estimated $213K.
  • Mackenzie Financial first reported a position in Madrigal Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Mackenzie Financial's Madrigal Pharmaceuticals position peaked at $236K in Q1 2023.
  • 257 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2024.

Based on Mackenzie Financial's 13F filing for Q2 2024, filed 14 Aug 2024.